Theriva Biologics Inc

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

TOVX$0.17-0.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands except share and par value amounts)


· December 31, · December 31,
· · 2023 · · 2022
Assets · ·
· ·
Current Assets · ·
Cash and cash equivalents	$23,177	$41,786
Tax credit receivable	1,812	—
Prepaid expenses and other current assets	2,414	3,734
Total Current Assets	27,403	45,520

Non-Current Assets
Property and equipment, net	422	345
Restricted cash	102	99
Right of use asset	1,759	1,199
In-process research and development	19,755	19,150
Goodwill	5,700	5,525
Deposits and other assets	78	23
Total Assets	$55,219	$71,861
Liabilities and Stockholders’ Equity

Current Liabilities:
Accounts payable	$770	$915
Accrued expenses	2,995	1,496
Accrued employee benefits	1,517	1,403
Contingent consideration, current portion	—	2,973
Deferred research and development tax credit-current portion	906	—
Loans payable-current	63	57
Operating lease liability-current portion	487	216
Total Current Liabilities	6,738	7,060

Non-current Liabilities
Non-current contingent consideration	6,274	7,211
Loan Payable - non-current	162	221
Deferred tax liabilities, net	—	1,618
Non-current deferred research and development tax credit	906	—
Non-current operating lease liability	1,442	1,187
Total Liabilities	15,522	17,297

Commitments and Contingencies	—	—
Temporary Equity
Series C convertible preferred stock, $0.001 par value; 10,000,000 authorized;275,000 issued and outstanding	2,006	2,006
Series D convertible preferred stock, $0.001 par value; 10,000,000 authorized;100,000 issued and outstanding	728	728
Stockholders’ Equity:
Common stock, $0.001 par value; 350,000,000 shares authorized, 17,868,282 issued and 17,148,049 outstanding at December 31, 2023 and 15,844,061 issued and 15,123,828 outstanding at December 31, 2022	18	16
Additional paid-in capital	346,519	343,750
Treasury stock at cost, 720,233 shares at December 31, 2023 and at December 31, 2022	(288)	(288)
Accumulated other comprehensive income (loss)	32	(679)
Accumulated deficit	(309,318)	(290,969)
Total Stockholders‘ Equity	36,963	51,830

Total Liabilities and Stockholders’ Equity	$55,219	$71,861

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.